Armata Pharmaceuticals Stock Performance
| ARMP Stock | USD 6.00 0.19 3.07% |
On a scale of 0 to 100, Armata Pharmaceuticals holds a performance score of 6. The firm shows a Beta (market volatility) of -1.35, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Armata Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Armata Pharmaceuticals is expected to outperform it. Please check Armata Pharmaceuticals' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Armata Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Armata Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak primary indicators, Armata Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.07) | Five Day Return (2.76) | Year To Date Return (8.54) | Ten Year Return (98.78) | All Time Return (100.00) |
Last Split Factor 1:14 | Dividend Date 2019-05-10 | Last Split Date 2019-05-10 |
1 | What is the fair value estimate for Armata Pharmaceuticals Inc. stock in 2025 - Volume Spike Real-Time Stock Price Movement Reports - newser.com | 11/11/2025 |
2 | Can Armata Pharmaceuticals Inc. stock surprise with earnings upside - 2025 Big Picture Free AI Powered Buy and Sell Recommendations - newser.com | 11/14/2025 |
3 | Can Armata Pharmaceuticals Inc. stock retain market dominance - 2025 Biggest Moves Safe Swing Trade Setups - newser.com | 11/17/2025 |
4 | Can Armata Pharmaceuticals Inc. stock attract ESG investments - Trade Volume Summary High Accuracy Trade Signal Alerts - newser.com | 11/20/2025 |
5 | Will Armata Pharmaceuticals Inc. stock announce special dividend - Bull Run Real-Time Chart Breakout Alerts - Newser | 12/04/2025 |
6 | How Armata Pharmaceuticals Inc. stock reacts to bond yields - 2025 Volume Leaders High Yield Equity Trading Tips - Blm Sonu Canavar | 12/19/2025 |
7 | Will Armata Pharmaceuticals Inc. stock continue dividend increases - 2025 Price Targets Community Consensus Trade Alerts - ulpravda.ru | 01/08/2026 |
| Begin Period Cash Flow | 19.2 M | |
| Total Cashflows From Investing Activities | -1.9 M |
Armata Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 499.00 in Armata Pharmaceuticals on October 28, 2025 and sell it today you would earn a total of 101.00 from holding Armata Pharmaceuticals or generate 20.24% return on investment over 90 days. Armata Pharmaceuticals is currently generating 0.5631% in daily expected returns and assumes 7.3703% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than Armata, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Armata Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Armata Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 6.00 | 90 days | 6.00 | about 56.22 |
Based on a normal probability distribution, the odds of Armata Pharmaceuticals to move above the current price in 90 days from now is about 56.22 (This Armata Pharmaceuticals probability density function shows the probability of Armata Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Armata Pharmaceuticals has a beta of -1.35. This suggests as returns on its benchmark rise, returns on holding Armata Pharmaceuticals are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Armata Pharmaceuticals is expected to outperform its benchmark. Moreover Armata Pharmaceuticals has an alpha of 1.6806, implying that it can generate a 1.68 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Armata Pharmaceuticals Price Density |
| Price |
Predictive Modules for Armata Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Armata Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Armata Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Armata Pharmaceuticals is not an exception. The market had few large corrections towards the Armata Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Armata Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Armata Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.68 | |
β | Beta against Dow Jones | -1.35 | |
σ | Overall volatility | 0.83 | |
Ir | Information ratio | 0.10 |
Armata Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Armata Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Armata Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Armata Pharmaceuticals is way too risky over 90 days horizon | |
| Armata Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Armata Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.17 M. Net Loss for the year was (18.92 M) with loss before overhead, payroll, taxes, and interest of (21.04 M). | |
| Armata Pharmaceuticals currently holds about 36.98 M in cash with (37.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02. | |
| Armata Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Invivyd Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 |
Armata Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Armata Stock often depends not only on the future outlook of the current and potential Armata Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Armata Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 36.2 M | |
| Cash And Short Term Investments | 9.3 M |
Armata Pharmaceuticals Fundamentals Growth
Armata Stock prices reflect investors' perceptions of the future prospects and financial health of Armata Pharmaceuticals, and Armata Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Armata Stock performance.
| Return On Equity | -34.39 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (6.71) % | ||||
| Current Valuation | 381.37 M | ||||
| Shares Outstanding | 36.41 M | ||||
| Price To Earning | (1.65) X | ||||
| Price To Book | 2.11 X | ||||
| Price To Sales | 43.22 X | ||||
| Revenue | 5.17 M | ||||
| Gross Profit | (21.04 M) | ||||
| EBITDA | (41.11 M) | ||||
| Net Income | (18.92 M) | ||||
| Cash And Equivalents | 36.98 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 126.52 M | ||||
| Debt To Equity | 0.73 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | (2.64) X | ||||
| Cash Flow From Operations | (37.55 M) | ||||
| Earnings Per Share | (1.66) X | ||||
| Market Capitalization | 218.44 M | ||||
| Total Asset | 86.44 M | ||||
| Retained Earnings | (327.74 M) | ||||
| Working Capital | (36.94 M) | ||||
| Current Asset | 4.48 M | ||||
| Current Liabilities | 4.08 M | ||||
About Armata Pharmaceuticals Performance
Assessing Armata Pharmaceuticals' fundamental ratios provides investors with valuable insights into Armata Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Armata Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (551.06) | (578.61) | |
| Return On Tangible Assets | (0.23) | (0.25) | |
| Return On Capital Employed | (1.28) | (1.34) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | 0.35 | 0.37 |
Things to note about Armata Pharmaceuticals performance evaluation
Checking the ongoing alerts about Armata Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Armata Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Armata Pharmaceuticals is way too risky over 90 days horizon | |
| Armata Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Armata Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.17 M. Net Loss for the year was (18.92 M) with loss before overhead, payroll, taxes, and interest of (21.04 M). | |
| Armata Pharmaceuticals currently holds about 36.98 M in cash with (37.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02. | |
| Armata Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Invivyd Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 |
- Analyzing Armata Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Armata Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Armata Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Armata Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Armata Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Armata Pharmaceuticals' stock. These opinions can provide insight into Armata Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.